CLCD

Colucid Pharmaceuticals, Inc.

No insider bought or sold Colucid Pharmaceuticals, Inc. in the last 12 months

$0Bought, 12 mo

$0Sold, 12 mo

Follow CLCD

CLCD over the last year

Prices for CLCD aren't in yet.

CLCD after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

18 insider filings since 2016, newest first

CLCDSell

Thomas P. Mathers · CEO

$52K−1.0%Jan 5

CLCDSell

Linda C. Hogan · Head, Bus. Dev., Strategy

$91K−100.0%Jan 5

CLCDSell

Bernice Kuca · Head,Clin., Reg. Operations

$28K−2.0%Jan 4

CLCDSell

Matthew D Dallas · CFO

$53K−4.0%Jan 4

CLCDSell

Thomas P. Mathers · CEO

$58K−1.0%Dec 5

CLCDSell

Linda C. Hogan · Head, Bus. Dev., Strategy

$98K−100.0%Dec 5

CLCDSell

Bernice Kuca · Head,Clin., Reg. Operations

$27K−2.0%Dec 1

CLCDSell

Matthew D Dallas · CFO

$52K−3.0%Dec 1

CLCDSell

Thomas P. Mathers · CEO

$43K−1.0%Nov 7

CLCDSell

Linda C. Hogan · Head, Bus. Dev., Strategy

$53K−100.0%Nov 7

CLCDSell

Thomas P. Mathers · CEO

$56K−1.0%Oct 5

CLCDSell

Linda C. Hogan · Head, Bus. Dev., Strategy

$96K−100.0%Oct 5

CLCDSell

Thomas P. Mathers · CEO

A/s Novo · 10% owner

Linda C. Hogan · Head, Bus. Dev., Strategy

$969K−100.0%Sep 7

CLCDSell

Thomas P. Mathers · CEO

$141K−3.0%Sep 7

CLCDSell

Domain Partners Vi, L.P. · 10% owner

$1.3M−7.0%Aug 3

CLCDSell

Domain Partners Vi, L.P. · 10% owner

$1.0M−7.0%May 2

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.